ELAPRASE® (idursulfase) sustained improvement in selected somatic parameters.
ELAPRASE is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older. In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with ELAPRASE has reduced spleen volume similarly to that of adults and children 5 years of age and older.
The safety and efﬁcacy of ELAPRASE have not been established in pediatric patients less than 16 months of age.
Full Prescribing Information Important Safety Information